A First-in-Human Phase 1 Study of LY3866288 (LOXO-435), a Potent, Highly Isoform-Selective FGFR3 Inhibitor (FGFR3i ... The drug demonstrated a favorable safety profile, avoiding high-grade ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

WALTHAM, Mass. and BOULDER, Colo., April 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

June 3, 9:42 a.m. ET (8:42 a.m. CT)) A Phase 2 Study of Pemigatinib for Pre-treated Glioblastoma or Other Gliomas with Activating FGFR1-3 Alterations: Results from FIGHT-209 (Abstract #2003.

Bisphosphonates are the mainstay of osteoporosis therapy. Extensive clinical evaluation supports their utility in stemming progression of the disease and in reducing fracture risk. In the course ...

Tasurgratinib (also known as E-7090) is an oral selective FGFR1, FGFR2, and FGFR3 inhibitor that, if approved, will join other drugs in the class on the market, including Incyte’s Pemazyre ...

We previously reported that fibroblast growth factor receptor 1 (FGFR1) is overexpressed in a subset of human CRPC bone metastases, and that FGFR1 overexpression of both α and β isoforms drives bone ...

This paper investigates how isoform II of transcription factor RUNX2 promotes cell survival and proliferation in oral squamous cell carcinoma cell lines. The authors used gain and loss of function ...

Several FGFR inhibitors, with similar potencies against FGFR1-3 or FGFR1-4, have been approved and demonstrated modest clinical benefits in FGFR-altered urothelial carcinoma and bile duct cancer. The ...

Human RUNX2 isoform II is overexpressed and associated with poor prognosis in OSCC. Figure 1-figure supplement 1. Lower RUNX2 isoform I expression is associated with poor overall survival in OSCC ...